SUPERNUS PHARMACEUTICALS, INC. Operating Lease Liability
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Operating Lease Liability of $40.17 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-03
- 2026-06-30: Operating Lease, Liability $40.17M.
- 2026-03-31: Operating Lease, Liability $40.90M.
- 2025-12-31: Operating Lease, Liability $40.98M.
- 2025-09-30: Operating Lease, Liability $42.21M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $40.17M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $40.90M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $40.98M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $42.21M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $31.77M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $32.30M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $34.27M 10-K · filed 2026-03-02 |
| 2024-09-30 | $38.15M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $39.98M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $42.13M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $41.53M 10-K · filed 2025-02-25 |
| 2023-09-30 | $42.32M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $42.20M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $44.09M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $42.79M 10-Q · filed 2023-11-08 |
| 2021-12-31 | $47.77M 10-K · filed 2022-04-13 |
| 2020-12-31 | $32.34M 10-K · filed 2021-03-08 |
| 2020-03-31 | $34.26M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $33.27M 10-Q · filed 2020-05-15 |
| 2019-09-30 | $30.40M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $30.89M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $31.07M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |